SEC Form 10-Q filed by CRISPR Therapeutics AG
$CRSP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/14/2025 | $60.00 → $99.00 | In-line → Outperform | Evercore ISI |
2/12/2025 | $35.00 | Sell → Hold | TD Cowen |
2/3/2025 | $65.00 | Buy | H.C. Wainwright |
8/6/2024 | $88.00 → $84.00 | Buy | Needham |
8/2/2024 | $90.00 | Buy | Rodman & Renshaw |
6/28/2024 | Neutral | Guggenheim | |
2/15/2024 | Peer Perform | Wolfe Research | |
12/11/2023 | $30.00 | Market Perform → Underperform | TD Cowen |
3/A - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)
4 - CRISPR Therapeutics AG (0001674416) (Issuer)